---
title: "BTIG Reaffirms Their Buy Rating on Guardant Health (GH)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285844932.md"
description: "BTIG analyst Mark Massaro has reaffirmed a Buy rating on Guardant Health (GH) with a price target of $145.00, while the shares closed at $95.70. On the same day, TD Cowen's Daniel Brennan also issued a Buy rating, but Evercore ISI maintained a Hold rating. Massaro has an average return of -4.7% and a 31.91% success rate on his stock recommendations."
datetime: "2026-05-10T13:43:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285844932.md)
  - [en](https://longbridge.com/en/news/285844932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285844932.md)
---

# BTIG Reaffirms Their Buy Rating on Guardant Health (GH)

BTIG analyst Mark Massaro reiterated a Buy rating on Guardant Health on May 8 and set a price target of $145.00. The company’s shares closed last Friday at $95.70.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Massaro covers the Healthcare sector, focusing on stocks such as Cerus, SOPHiA GENETICS, and NeoGenomics. According to TipRanks, Massaro has an average return of \-4.7% and a 31.91% success rate on recommended stocks.

In addition to BTIG, Guardant Health also received a Buy from TD Cowen’s Daniel Brennan in a report issued on May 8. However, on the same day, Evercore ISI maintained a Hold rating on Guardant Health (NASDAQ: GH).

### Related Stocks

- [GH.US](https://longbridge.com/en/quote/GH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [CERS.US](https://longbridge.com/en/quote/CERS.US.md)
- [SOPH.US](https://longbridge.com/en/quote/SOPH.US.md)
- [NEO.US](https://longbridge.com/en/quote/NEO.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Pictet Asset Management Holding SA Sells 89,386 Shares of Guardant Health, Inc. $GH](https://longbridge.com/en/news/284963012.md)